Thanks for posting, pierreluke.
This is an oral presentation, not a poster, which gives it extra prominence. Also notice date--coming right up--
Asterias today announced that clinical data from its AST-VAC1 (antigen-presenting autologous dendritic cells) immunotherapy clinical program will be presented during an oral session at the upcoming American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting, to be held on May 4-7, 2016 in Washington, D.C.
"...the lift on the partial hold will affect several drugs in the pipeline along with their extensive library of MPAC's...."
Exactly what I was thinking, kad.